Lanosterol eye drops for cataract treatment
HPBCD was found to deliver lanosterol (a tetracyclic triterpenoid) active substance into the crystalline lens of the eye. This delivery
Tag: cataract
Oculis started Phase II clinical trial with OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases, announced